- Trials with a EudraCT protocol (440)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
440 result(s) found for: Rectal Cancer.
Displaying page 11 of 22.
EudraCT Number: 2019-003011-55 | Sponsor Protocol Number: MesaCAPP | Start Date*: 2020-07-23 | ||||||||||||||||
Sponsor Name:Karolinska Institute | ||||||||||||||||||
Full Title: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome | ||||||||||||||||||
Medical condition: Lynch Syndrome, which is increasing the risk of developing colorectal cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004475-12 | Sponsor Protocol Number: TTD-04-03 | Start Date*: 2005-04-21 |
Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos | ||
Full Title: Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancer | ||
Medical condition: Pre-surgical Locally advanced rectal cancer treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001986-18 | Sponsor Protocol Number: CMEK162X2116 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||
Sponsor Name:Array BioPharma Inc. | ||||||||||||||||||||||||||||
Full Title: A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer | ||||||||||||||||||||||||||||
Medical condition: Mutant RAS or wild-type (WT) RAS metastatic colorectal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) BE (Completed) IT (Prematurely Ended) NL (Completed) DE (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000845-64 | Sponsor Protocol Number: CCR4085 | Start Date*: 2014-12-17 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection | |||||||||||||
Medical condition: colorectal cancer with liver metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000467-14 | Sponsor Protocol Number: IEO223 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||||||||||||
Full Title: Colorectal cancer, Vitamina D and microbiota: towards new preventive strategies. A double blind Phase II randomized trial, ColoViD | |||||||||||||||||||||||
Medical condition: Colon rectal cancer stage I - III | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003714-14 | Sponsor Protocol Number: 4213000 | Start Date*: 2020-06-30 | |||||||||||
Sponsor Name:TheraOp gGmbH | |||||||||||||
Full Title: Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients | |||||||||||||
Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the left-sided colon or rectum with metastases (metastatic colorectal cancer), primarily non-resectable or surgery refused by the patient, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001387-28 | Sponsor Protocol Number: NL73559.091.20 | Start Date*: 2020-06-22 | ||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||
Full Title: 18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology. | ||||||||||||||||||
Medical condition: 75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003740-62 | Sponsor Protocol Number: ABCSG R03 (96) /TAKO 06 | Start Date*: 2005-10-27 |
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | ||
Full Title: Preoperative chemoradiation with capecitabine and cetuximab within a multidisciplinary therapeutic approach in patients with operable T3-T4 rectal cancer: a phase II study | ||
Medical condition: locally advanced operable rectal carcinoma (cT3-T4NxM0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017731-17 | Sponsor Protocol Number: AIO-KRK-0109 | Start Date*: 2011-02-01 | |||||||||||
Sponsor Name:AIO-Studien-gGmbh | |||||||||||||
Full Title: An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type | |||||||||||||
Medical condition: non-resectable metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000394-96 | Sponsor Protocol Number: NEOGAP-CRC-01 | Start Date*: 2023-01-31 | |||||||||||
Sponsor Name:NEOGAP Therapeutics AB | |||||||||||||
Full Title: A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer | |||||||||||||
Medical condition: Stage IV colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006629-23 | Sponsor Protocol Number: 61186372GIC2002 | Start Date*: 2022-08-23 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | |||||||||||||
Medical condition: Advanced or Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003509-16 | Sponsor Protocol Number: FLIBER | Start Date*: 2018-03-02 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | ||||||||||||||||||
Full Title: Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) | ||||||||||||||||||
Medical condition: Metastatic Colo-Rectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004211-31 | Sponsor Protocol Number: CCR3894 | Start Date*: 2014-08-20 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | ||
Medical condition: Adverse effects of radiotherapy for pelvic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003957-10 | Sponsor Protocol Number: SCOT-2007-01 | Start Date*: 2011-01-31 | ||||||||||||||||
Sponsor Name:Greater Glasgow Health Board (GGHB)/ University of Glasgow | ||||||||||||||||||
Full Title: Short Course Oncology Therapy - A study of adjuvant chemotherapy in colorectal cancer | ||||||||||||||||||
Medical condition: Colorectal Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DK (Completed) ES (Completed) SE (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006332-23 | Sponsor Protocol Number: MOMA261111 | Start Date*: 2012-05-19 | |||||||||||
Sponsor Name:ARCO | |||||||||||||
Full Title: PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCE... | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000553-40 | Sponsor Protocol Number: CNIS793E12201 | Start Date*: 2021-11-18 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer th... | ||||||||||||||||||
Medical condition: metastatic colorectal cancer (mCRC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) DE (Completed) HU (Prematurely Ended) ES (Temporarily Halted) BE (Completed) IT (Prematurely Ended) FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004139-23 | Sponsor Protocol Number: 62202-677 | Start Date*: 2006-08-18 |
Sponsor Name:University of Cologne | ||
Full Title: An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with cetuximab and 5-FU for advanced rectal cancer | ||
Medical condition: advanced adenocarcinoma of the rectum | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-002264-41 | Sponsor Protocol Number: IMGC936-0901 | Start Date*: 2022-02-21 | |||||||||||||||||||||||||||||||
Sponsor Name:ImmunoGen, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003671-60 | Sponsor Protocol Number: NO-CUT | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: TOTAL NEOADJUVANT TREATMENT WITHOUT SURGERY FOR LOCALLY ADVANCED RECTAL CANCER: PROSPECTIVE CLINICAL TRIAL TO ASSESS TUMOR COMPLETE RESPONSE, CIRCULATING TUMOR GENETIC AND EPIGENETIC BIOMARKERS, AN... | |||||||||||||
Medical condition: Adenocarcinoma of the medium/lower rectum in Stage II (cT3-4 N0) or Stage III (cT1-4, N1-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001920-36 | Sponsor Protocol Number: NIMAO/2018-01/JF-01 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo... | |||||||||||||
Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
